Absorptive Clearance in the Cystic Fibrosis Airway

• ClinicalTrials.gov Identifier: NCT00541190
• Recruitment Status: Completed
• First Posted: October 10, 2007
• Results First Posted: February 3, 2012
• Last Update Posted: August 24, 2017
• Sponsor: University of Pittsburgh
• Information provided by (Responsible Party): Tim Corcoran, University of Pittsburgh

Study Description

Brief Summary:

The objective of this overall project is to develop a new aerosol-based technique for quantifying liquid absorption in the airways of subjects with cystic fibrosis(CF) that can be used to help develop new therapies. In CF, mutations in the CF gene result in dysfunction of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel on the cells that line the airway epithelium, causing improper fluxes of ions such as sodium, chloride, and bicarbonate. The so called "low volume" hypothesis of CF pathogenesis contends that abnormal absorption of ions from the airways causes excessive absorption of liquid, resulting in an airway surface liquid layer that is dehydrated and difficult to clear. Here we are measuring the absorption rate of a radiolabeled small molecule (DTPA) from the lungs of cystic fibrosis patients and healthy controls. We hypothesize that the molecule will absorb more quickly in cystic fibrosis patients. Further studies will be performed to determine if DTPA absorption is related to liquid absorption in the airways.

Condition or disease	Intervention/treatment	Phase
Cystic Fibrosis	Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 21 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Absorptive Clearance in the Cystic Fibrosis Airway
• Study Start Date: October 2007
• Actual Primary Completion Date: April 2008
• Actual Study Completion Date: April 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: cystic fibrosis; Cystic fibrosis patients	Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA; Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
Experimental: healthy controls; Healthy control subjects	Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA; Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.

Outcome Measures

Primary Outcome Measures :

1. Absorptive Clearance Rate [ Time Frame: single measurement ]
   The absorptive clearance rate is the percentage of the radiolabeled small molecule DTPA that is cleared through absorption over a 60 minute period. Total DTPA clearance includes absorptive and mucociliary components. The mucociliary component is determined by measuring the clearance of a radiolabeled particle over the same period (Technetium 99m sulfur colloid; Tc-SC), and subtracted from total DTPA clearance in order to determine the absorptive component. Here we specifically report absorption from the central lung zone to capture the behavior within the airways.

Secondary Outcome Measures :

1. Mucociliary Clearance Rate [ Time Frame: single measurement ]
   Mucociliary clearance rate represents the rate at which the lungs clear an inhaled particulate. Here it specifically represents the percentage of inhaled Technetium 99m sulfur colloid cleared from the lungs over a 60 minute period. This is reported based on "whole lung" areas to allow comparisons with previous studies.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Cystic fibrosis subjects and healthy controls
• Age ≥ 18 years
• Diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms (CF subjects)
• Clinically stable as determined by the investigator (pulmonologist)

Exclusion Criteria:

• Reactive airways disease
• Tobacco smokers (regular smoking within 6 months of enrollment)
• Positive urine pregnancy test on the day of testing
• FEV1p value of < 50%
• SaO2 < 92%, or if they require supplemental oxygen.
• Subjects performing other radioisotope studies within the last 2 weeks will be excluded.
• Healthy subjects with any history of lung disease will be excluded.
• Women currently breastfeeding
• Subjects not willing to stop treatments with inhaled hypertonic saline for 48 hours in advance of the study.

Contacts and Locations

Locations

United States, Pennsylvania

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

Sponsors and Collaborators

University of Pittsburgh

Investigators

• Principal Investigator: Timothy E Corcoran, Ph.D.; University of Pittsburgh

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Locke LW, Myerburg MM, Weiner DJ, Markovetz MR, Parker RS, Muthukrishnan A, Weber L, Czachowski MR, Lacy RT, Pilewski JM, Corcoran TE. Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung. Eur Respir J. 2016 May;47(5):1392-401. doi: 10.1183/13993003.01880-2015. Epub 2016 Mar 23.

Corcoran TE, Thomas KM, Myerburg MM, Muthukrishnan A, Weber L, Frizzell R, Pilewski JM. Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. Eur Respir J. 2010 Apr;35(4):781-6. doi: 10.1183/09031936.00059009. Epub 2009 Aug 28.

• Responsible Party: Tim Corcoran, Assistant Professor, University of Pittsburgh
• ClinicalTrials.gov Identifier: NCT00541190
• Other Study ID Numbers: PRO07060240; NIH K25 HL081533-02
• First Posted: October 10, 2007
• Results First Posted: February 3, 2012
• Last Update Posted: August 24, 2017
• Last Verified: July 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Keywords provided by Tim Corcoran, University of Pittsburgh:

cystic fibrosis; mucociliary clearance; outcome measures

Additional relevant MeSH terms:

Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases